Report : North America Defibrillator Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Implantable Cardioverter Defibrillator and External) and End User (Hospitals and Clinics, Prehospital Care, Public Access, Home Care Settings, and Alternate Care Facilities)
Implantable Cardioverter Defibrillator Segment to Dominate North America Defibrillator Market during 2019–2028
According to a new market research study on “North America Defibrillator Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product and End User,” is expected to reach US$ 6,597.93 million by 2028 from US$ 4,575.28 million in 2021. The market is estimated to grow at a CAGR of 5.4% from 2021 to 2028. Increasing prevalence of cardiovascular diseases is the major factor driving the growth of the North America defibrillator market. However, cost and performance issues related to implantable and automated external defibrillators may hinder the growth of North America defibrillator market. The report provides trends prevailing in the North America defibrillator market along with the drivers and restraints pertaining to the market growth.
In North America, the US was severely impacted by the emergence of the COVID-19 pandemic. The country has had the highest number of COVID-19 patients with over 68 million reported cases and more than 856,000 deaths as per data given by the US Department of Health & Human Services and CDC as of January 19, 2022.The US is going through another surge in COVID-19 cases due to the omicron variant of SARS-CoV-2, which is expected to peak by January-end, 2022. Mexico is going through its biggest COVID-19 wave and has been registering a massive surge in COVID-19 cases. Similarly, Canada has gone through a recent wave of COVID-19 with the total number of cases rising to over ~2.84 million and 32,000 deaths, as of January 20th, 2022. As the hospital admissions and pressure on the healthcare infrastructure rose, the demand for defibrillators and other medical devices increased owing to their importance in in-hospital resuscitation and in-home settings with implantable cardioverter?defibrillator. Initial assessments showed fast, abnormal heart rates as a symptom experienced by many COVID-19 patients, and therefore, various recommendations and bulletins were issued by the CDC and the American College of Cardiology warning patients about the potential risk for cardiac patients and encouraging the use of automated external defibrillators along with various other precautions. As people with heart conditions were at the highest risk of contracting SARS-CoV-2, the demand for defibrillators in hospitals peaked, which were needed to treat cardiac arrests in critically ill patients. Studies conducted by various authorities showed a rise in the importance of defibrillators in hospitals and an increase in the usage of defibrillators in other settings. Organizations such as the World Health Organization (WHO), CDC, and the American College of Cardiology emphasized the presence of defibrillators in hospitals as an essential tool for combating the disease. The International Liaison Committee on Resuscitation or ILCOR also updated their guidelines through focused defibrillation training to avoid compromising the care of the patient experiencing tachyarrhythmia arrests, which also protected the caregiver from exposure to the virus. A 2020 study titled “Implantable Cardioverter?Defibrillator Shocks During COVID?19 Outbreak” by Adabag et.al., used the Medtronic Carelink database during 2019–2020 to determine the incidence of implantable defibrillator shock episodes among patients residing in New York, New Orleans, and Boston. The study found a significant increase in defibrillator shock episodes during the COVID-19 pandemic compared to 2019. Another study published in 2021 titled “The Role of the Automated Implantable Cardioverter Defibrillator (AICD) for Secondary Prevention in the COVID-19 Era,” presented a case of COVID-19 in a New York City Hospital who rapidly developed sudden cardiac arrest after presenting to the emergency room. The study concluded by emphasizing the use of automated implantable cardioverter defibrillator (AICD) with subclinical cardiac injury in COVID-19 patients post-recovery showing an upward trend. The study recommended the use of AICD as a secondary preventive measure to prevent recurrence of SCA and sudden cardiac deaths. Various studies, rise in the number of COVID-19 cases, and emphasis laid down on the use of defibrillators as a preventive instrument in preventing cardiac arrests by various governmental and nongovernmental organizations showcased a positive impact on the defibrillator market with the application of defibrillators rising in hospitals and nonhospital.
The North America defibrillator market is segmented into product, end user, and country. Based on product, the market is segmented into implantable cardioverter defibrillator (ICD) and external. In 2020, the implantable cardioverter defibrillator segment held the largest share North America defibrillator market. The implantable cardioverter defibrillator is further sub-segmented into transvenous ICD and subcutaneous ICD. The transvenous ICD segment accounts for largest market share in the 2020. Similarly, the external segment is sub-segmented into manual, wearable, and fully automated external defibrillators. In 2020, the manual segment held the largest share of the market. Based on end user, the North America defibrillator market is segmented into hospitals and clinics, prehospital care, public access, home care settings, and alternate care facilities. The hospitals and clinics segment held the largest share of the market in 2020. Similarly, based on country, the market is segmented into US, Canada, and Mexico. The US contributed a substantial share in 2020.
Abbott; Biotronik, Inc; Boston Scientific Corporation; Koninklijke Philips N.V.; Medtronic; Nihon Kohden Corporation; Shenzhen Mindray Biomedical Electronics Co., Ltd; and ZOLL MEDICAL CORPORATION are among the leading companies in the North America defibrillator market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, ZOLL Medical Corporation announced a launch of remote view technology on the X Series monitor/defibrillator developed for EMS agencies.
North America Defibrillator Market, By Country, 2020 and 2028 (%)
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org